LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC

BACKGROUND: LCL161, a novel Smac mimetic, is known to have anti-tumor activity and improve chemosensitivity in various cancers. However, the function and mechanisms of the combination of LCL161 and paclitaxel in non-small cell lung cancer (NSCLC) remain unknown. METHODS: Cellular inhibitor of apopto...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Exp Clin Cancer Res
Prif Awduron: Yang, Chengcheng, Wang, Huangzhen, Zhang, Boxiang, Chen, Yimeng, Zhang, Yamin, Sun, Xin, Xiao, Guodong, Nan, Kejun, Ren, Hong, Qin, Sida
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2016
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5062899/
https://ncbi.nlm.nih.gov/pubmed/27737687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0435-7
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg